NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
8 hedge funds and large institutions have $114K invested in NLS Pharmaceutics Warrant in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
2% less ownership
Funds ownership: 11.02% → 9.01% (-2%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
77% less capital invested
Capital invested by funds: $487K → $114K (-$373K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$121 |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WVP
1
Worth Venture Partners
Fort Lee,
New Jersey
| $38K | -$121 | -500 | -0.3% |
|
|
ACM
2
Altium Capital Management
New York
| $24K | – | – | – |
|
|
AC
3
Ayrton Capital
Westport,
Connecticut
| $20K | – | – | – |
|
|
EAM
4
Empery Asset Management
New York
| $18K | – | – | – |
|
5
Hudson Bay Capital Management
Stamford,
Connecticut
| $12K | – | – | – |
|
|
WAM
6
Warberg Asset Management
Winnetka,
Illinois
| $2K | -$2 | -10 | -0.1% |
|
|
AC
7
Armistice Capital
New York
| $60 | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| – | +$23 | +96 | +5% |
|
NLSPW Hedge Fund Activity: Q2 2022 in Review
8 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q2 2022, worth a combined $114K — down 77% from $487K a quarter earlier.
Fund positioning in NLSPW was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $23. The largest seller was Worth Venture Partners, cutting an estimated $121.
- 8 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $114K of NLS Pharmaceutics Warrant stock for Q2 2022, down 77% quarter-over-quarter.
- 0 funds opened new NLS Pharmaceutics Warrant positions in Q2 2022 and 0 closed out.
- The largest NLS Pharmaceutics Warrant buyer in Q2 2022 was UBS Group, an estimated $23 added.
- The largest NLS Pharmaceutics Warrant seller in Q2 2022 was Worth Venture Partners, an estimated $121 sold.
Based on aggregated 13F filings for Q2 2022.